Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer

Currently, tamoxifen is the only drug approved for reduction of breast cancer risk in premenopausal women. The significant cardiovascular side effects of tamoxifen, coupled with lack of a survival benefit, potential for genotoxicity, and failure to provide a significant risk-reduction for estrogen r...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Veronica C., Dietze, Eric C., Jovanovic-Talisman, Tijana, McCune, Jeannine S., Seewaldt, Victoria L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658387/
https://www.ncbi.nlm.nih.gov/pubmed/33194937
http://dx.doi.org/10.3389/fpubh.2020.509714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658387/
https://www.ncbi.nlm.nih.gov/pubmed/33194937
http://dx.doi.org/10.3389/fpubh.2020.509714

Ejemplares similares